MIT researchers introduce CuRVE, a protein-labeling technique enabling uniform staining across entire tissues.
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.